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Nadia R. Sutton, MD, MPH, David J. Pinsky, MDSEE PAGE 1801E verything we once thought we knew about thetherapeutic use of estrogen for the preventionof cardiovascular disease (CVD) in women is
wrong (1). Everything we once knew about the role
of sex in CVD is still right; men are affected a decade
earlier than women. We are still enamored with the
idea that sex steroids, particularly androgens, have,
if not a causal role in CVD development, at least an as-
sociation. We simply cannot get the notion out of our
heads that androgens (or relative lack of estrogen)
drive endothelial dysfunction and atherogenesis,
and potentially, even plaque fracture. In this light,
new studies that assess the risk associated with low
levels of a particularly abundant sex steroid (dehy-
droepiandrosterone [DHEA] and its sulfated congener
[DHEA-S], which can serve as the precursor substrate
for either testosterone or estradiol) are of particular
interest.
Previous studies have examined the relationship
between DHEA and DHEA-S and cardiovascular out-
comes; these studies yielded conﬂicting results (2–6).
Prospective population-based studies on DHEA-S and
mortality in women have consistently shown no as-
sociation between DHEA-S and all-cause and CVD
mortality (6). Prospective population-based studies in
men have either shown no relationship between
DHEA-S and outcomes, or have shown that lower
DHEA-S levels are associated with higher all-cause or
CVD mortality (4,5,7,8). These apparent discrepancies
have been attributed to differences in the populations
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DHEA-S levels, such as age (decreases DHEA-S) and
smoking (positively correlated with DHEA-S). DHEA-S
levels have also been found to vary between pop-
ulations; for example, men in California had higher
levels than Japanese men, and DHEA-S levels
were elevated in British women relative to Japanese
women (9,10).In this issue of the Journal, Tivesten et al. (11) revisit
the question of whether DHEA and DHEA-S predict
major coronary heart disease (CHD) events in elderly
men. The primary endpoints were major CHD events
(hospitalization for acute myocardial infarction, un-
stable angina, revascularization, or death from CHD)
and cerebrovascular disease (CBD) events (hospitali-
zation for stroke or transient ischemic attack, or death
from stroke) as determined by the use of the Swedish
Causes of Death Register. This database is a particu-
larly robust registry because only 3 of 2,416 study
subjects were lost to follow-up. The study included
2,416 men (ages 69 to 81 years). After a median follow-
up of 5.2 years, 302 participants had a CHD event, and
225 had a CBD event. An inverse association was
observed between age-adjusted DHEA and DHEA-S
levels and CHD events, with hazard ratios of 0.82
(95% conﬁdence interval: 0.73 to 0.93) for DHEA and
0.86 (95% conﬁdence interval: 0.77 to 0.97) for DHEA-
S. No signiﬁcant association was found between
DHEA/-S and CBD events. The relationship between
DHEA/-S and CHD events remained signiﬁcant after
adjustment for traditional cardiovascular risk factors,
including smoking, hypertension, diabetes, body
mass index (BMI), and renal function, as well as for
high-sensitivity C-reactive protein (hsCRP) levels and
the apolipoprotein B/A1 ratio. Within the composite
endpoint, deaths from CHD and hospitalization for
unstable angina were inversely associated with DHEA
and DHEA-S, although hospitalization for myocardial
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individually did not reach signiﬁcance. In these anal-
yses, DHEA/-S levels were adjusted for age and the
time of day for sample collection, but not for other
cardiovascular risk factors.
Several strengths of this study deserve mention.
This was the largest prospective trial that evaluated
the relationship between DHEA and DHEA-S levels
and CHD and CBD events to date. It detected a sig-
niﬁcant association between lower DHEA/-S levels
and CHD events after a 5-year follow-up. This associ-
ation appeared to be maintained even after account-
ing for the recognized confounders of DHEA and
DHEA-S levels of age and diurnal variation, and after
adjusting for other CVD risk factors, including smok-
ing, hypertension, diabetes, BMI, renal function,
hsCRP, and the apolipoprotein B/A1 ratio. Because
renal function has not traditionally been adjusted for
in previous publications that describe the relationship
between DHEA/-S and cardiovascular outcomes, it is
noteworthy that in this study, the association between
DHEA/-S and CHD outcomes persisted even after
accounting for this important variable. Furthermore,
this study measured both DHEA and DHEA-S, and
showed a more pronounced negative relationship
between mortality and DHEA than that with DHEA-S.
This suggests that DHEA could be a more important
predictor of outcomes, despite low plasma DHEA
concentrations relative to DHEA-S. This has signiﬁ-
cant implications, because most previous negative
studies examined only DHEA-S levels. If this ﬁnding is
borne out in subsequent studies, then consideration
should be given to re-examination of banked samples
from populations (such as women and younger men)
in whom no differences in the effect of DHEA-S on
cardiovascular outcomes were previously seen.
In general, drawbacks to any DHEA study are related
to DHEA’s diurnal pattern and generally low plasma
concentration. Certainty, regarding the results of the
ﬁndings in the study by Tivesten et al. (11), they are
diminished when one considers a previous study by
this same group that used a largely overlapping cohort
of elderly Swedish men (12). This earlier study showed
that although DHEA and DHEA-S predicted all-cause
and cardiovascular mortality in those who wereyounger than 75 years of age, therewas no difference in
these speciﬁc endpoints in those who were older than
75 years of age (12). Because of the similar populations
studied, albeit with slightly different endpoints, a
question is raised of whether the association between
DHEA and DHEA-S and CHD events persists in men
older than 75 years of age. This would have im-
plications for the applicability of DHEA as a biomarker
for CHD events in this age group, given the high in-
cidence of CHD inmen older than 75 years of age. There
are other methodological issues that diminish conﬁ-
dence in the data, such as the self-reporting of base-
line demographic characteristics. Another cautionary
note in interpreting the study (11) stems from some
of the subset analyses, such as adjustment for the
sites under study, and the somewhat arbitrary exclu-
sion of the ﬁrst 2.6 years of follow-up.
Although many biomarkers of future coronary
events have been studied, we have yet to identify a
molecule that precisely predicts future events (12–18).
Despite advances in primary and secondary preven-
tion of CHD events, there is still a high incidence of
death due to CHD, including sudden cardiac death in
individuals who do not have traditional coronary dis-
ease risk factors (19). There is room for improvement in
our collective ability to identify those at high risk for
future events. Furthermore, some biomarkers have
stronger associations with outcomes than others. An
ideal solution might be the use of weighted patterns
of biomarkers, which would take into consideration
typical biochemical interactions and provide a
personalized biochemical ﬁngerprint to more exactly
deﬁne an individual’s risk of future events. DHEA may
represent a new arrow in the quiver of biomarkers.
In such a new paradigm, biomarker patterns could
suggest intensiﬁcation of medical therapy for those at
the highest risk. The ﬁndings reported here should,
at the least, spur further interest in understanding
DHEA as a biomarker of CVD risk.
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